使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health first-quarter earnings conference call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to turn the conference over to the company's management. Please go ahead.
各位女士、先生,感謝您稍候,歡迎參加 Elevance Health 第一季財報電話會議。(接線員指示)提醒各位,今天的會議將被錄音。現在我想把會議交給公司管理團隊。請開始。
Nathan Rich - Vice President of Investor Relations
Nathan Rich - Vice President of Investor Relations
Good morning, and welcome to Elevance Health's first-quarter 2026 earnings conference call. My name is Nathan Rich, Vice President of Investor Relations. With us on the earnings call are Gail Boudreaux, President and CEO; Mark Kaye, our CFO; Felicia Norwood, our Chief Health Benefits Officer; Morgan Kendrick, President of our Commercial Health Benefits Business; and Aimee Dailey, President of our Government Health Benefits business.
各位早安,歡迎參加 Elevance Health 2026 年第一季財報電話會議。我是投資人關係副總裁 Nathan Rich。今天與會的有總裁暨執行長 Gail Boudreaux;財務長 Mark Kaye;健康福利長 Felicia Norwood;商業健康福利事業總裁 Morgan Kendrick;以及政府健康福利事業總裁 Aimee Dailey。
Gail will open the call by highlighting our first-quarter performance and the actions we are taking to advance our strategic priorities. Mark will then discuss our financial results and revised outlook in greater detail. After our prepared remarks, the team will be available for Q&A. During the call, we will reference certain non-GAAP financial measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website, elevancehealth.com.
Gail 將先就第一季表現作重點說明,並分享我們為推進策略優先事項所採取的行動。接著 Mark 將更詳細說明我們的財務結果與修訂後的展望。在我們的準備發言之後,團隊將開放問答。在本次電話會議中,我們將提及若干非 GAAP 財務衡量指標。這些非 GAAP 指標與最直接可比的 GAAP 指標之調節表,已公布於我們的網站 elevancehealth.com。
We will also be making forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Elevance Health. These risks and uncertainties may cause actual results to differ materially from our current expectations. We advise listeners to carefully review the risk factors discussed in today's press release and in our quarterly filings with the SEC.
我們也將在本次電話會議中作出前瞻性陳述。聽眾請注意,這些陳述受到若干風險與不確定性影響,其中許多難以預測,且通常超出 Elevance Health 的控制範圍。這些風險與不確定性可能導致實際結果與我們目前的預期出現重大差異。我們建議聽眾仔細閱讀今日新聞稿以及我們向 SEC 提交之季度申報文件中所討論的風險因素。
I will now turn the call over to Gail.
現在我把電話會議交給 Gail。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Good morning and thank you for joining us. Healthcare is undergoing significant transformation, and it requires us to operate with greater speed, precision, and connectivity. Costs are rising, expectations are rising, and both member and care providers want a simpler, more integrated experience. At Elevance Health, our strategy remains clear: lower the cost of healthcare and simplify how people navigate the system.
各位早安,感謝各位加入。醫療保健正經歷重大轉型,這要求我們以更高的速度、精準度與連結性來運作。成本在上升、期待在上升,會員與醫療服務提供者都希望獲得更簡單、更整合的體驗。在 Elevance Health,我們的策略依然清晰:降低醫療保健成本,並簡化人們在體系中的就醫與使用流程。
What is evolving is how we execute. We are operating with greater alignment, accountability, and clarity across the enterprise, and that progress is showing up in our results. In the first quarter, our performance exceeded expectations, driven by underlying business strength, along with ACA seasonality and non-recurring investment income. While it is still early in the year, the trends we are seeing give us increased confidence in the trajectory of the business. That is why we are raising our full-year adjusted diluted earnings per share guidance to at least $26.75.
正在演進的是我們的執行方式。我們在全企業範圍內以更高的一致性、問責性與清晰度運作,而這些進展也反映在我們的成果上。第一季表現優於預期,主要受基本業務動能帶動,並受 ACA 季節性因素與一次性投資收益影響。雖然今年仍在初期,但我們所看到的趨勢讓我們對業務走勢更具信心。因此,我們將全年調整後稀釋每股盈餘(EPS)指引上調至至少 26.75 美元。
Our outlook remains grounded in prudent, achievable assumptions with clear visibility into the key drivers of performance supported by improving claims experience. We are advancing our strategy in several focused ways. First, we've realigned our leadership structure to strengthen coordination between Health Benefits and Carelon. We have streamlined accountability, aligned core functions more closely to the business, and brought decision-making closer to where the work is done. Those changes are designed to sharpen execution and create greater alignment across the enterprise.
我們的展望仍建立在審慎且可達成的假設之上,對關鍵績效驅動因素具備清楚能見度,並由改善中的理賠經驗所支撐。我們正以幾個聚焦方向推進策略。第一,我們已重新調整領導架構,以強化健康福利(Health Benefits)與 Carelon 之間的協同。我們精簡了問責機制,使核心職能更貼近業務,並將決策更靠近實際執行工作的前線。這些變革旨在提升執行力,並在全企業範圍內建立更高的一致性。
Second, we are embedding and scaling AI across clinical, operational, and administrative workflows, where it can have direct, measurable impact, and we are already seeing tangible results. These capabilities are improving how we engage members and how we manage costs. They are enabling earlier, more personalized interventions, strengthening decision-making through predictive analytics, and reducing administrative expense through automation. Together, these are driving greater efficiency and supporting more consistent performance over time.
第二,我們正把 AI 深度嵌入並擴大應用於臨床、營運與行政工作流程中,在可直接、可衡量的層面產生影響,而我們已看到具體成果。這些能力正在改善我們與會員互動的方式,以及我們管理成本的方式。它們使我們能更早進行更個人化的介入,透過預測分析強化決策,並藉由自動化降低行政費用。綜合而言,這些舉措正在提升效率,並支持我們隨時間推移展現更一致的績效。
Third, we are transforming how care is delivered through Carelon by advancing our integrated whole health approach. By combining CareBridge and our care-at-home capabilities into a single risk-based solution, we are driving higher engagement and stronger clinical outcomes. These programs have reduced hospital readmission by 20% and generated more than 10% savings on post-acute care, supported by integrated pharmacy, specialty care, and behavioral health.
第三,我們透過 Carelon 推進整合式全人健康(whole health)方法,正在改變照護的提供方式。我們將 CareBridge 與居家照護(care-at-home)能力整合為單一的風險承擔型解決方案,進而提升參與度並改善臨床結果。在整合藥局、專科照護與行為健康的支持下,這些方案已使住院再入院率降低 20%,並在急性後期照護(post-acute care)上創造超過 10% 的節省。
We continue to see strong demand for Carelon's capabilities, reinforcing its role as a driver of current performance and long-term growth. Let me turn to our first-quarter performance. In Medicaid, we are seeing early evidence that our actions are lowering costs, particularly in behavioral health and specialty pharmacy. That progress is being driven by more targeted, proactive interventions that allow us to engage earlier, coordinate care more effectively, and support members in the most appropriate settings.
我們持續看到市場對 Carelon 能力的強勁需求,進一步鞏固其作為當前績效與長期成長驅動因素的角色。接下來談第一季表現。在 Medicaid 方面,我們看到初步證據顯示,我們的行動正在降低成本,尤其是在行為健康與專科藥局領域。這些進展來自更具針對性、更加主動的介入,使我們能更早接觸會員、更有效地協調照護,並在最適切的場域支持會員。
We are addressing rapid growth in ABA therapy through rigorous clinical oversight, and we're using predictive analytics to identify members at risk of substance use disorder before adverse events occur. In Medicare Advantage, the steps we have taken to reposition the business are driving improved performance, and we remain on track to achieve an operating margin of at least 2% in 2026. We were also encouraged to see CMS address the portion of the funding challenges in the final rates for 2027.
我們透過嚴謹的臨床監督來因應 ABA 治療的快速成長,並運用預測分析在不良事件發生前,辨識有物質使用障礙風險的會員。在 Medicare Advantage 方面,我們為重新定位該業務所採取的措施正帶動績效改善,我們仍按計畫在 2026 年達成至少 2% 的營業利益率。我們也樂見 CMS 在 2027 年最終費率中處理了部分資金面挑戰。
As we prepare for bid submissions, we will remain disciplined and continue to prioritize plans that deliver long-term value while supporting progress toward our financial objectives. Regarding the notice we received from CMS in February related to historical risk adjustment data, we are engaging constructively with the agency and making steady progress toward resolution. We stand firmly behind the integrity of our risk adjustment program, supported by rigorous oversight and governance.
在準備投標提交(bid submissions)之際,我們將維持紀律,並持續優先推動能創造長期價值、同時支持我們財務目標進展的方案。關於我們在 2 月收到 CMS 就歷史風險調整資料所發出的通知,我們正以建設性方式與主管機關溝通,並穩步推進以達成解決。我們堅定捍衛風險調整計畫的完整性,並以嚴謹的監督與治理作為支撐。
Importantly, this matter does not affect our outlook or how we serve our members. And it does not change how we are managing the business or our expectations for performance. In commercial, we maintained a disciplined pricing approach for 2026 to ensure appropriate returns and our first-quarter performance reflects that focus.
重要的是,此事項不影響我們的展望或我們服務會員的方式。也不會改變我們經營管理業務的方式或我們對績效的預期。在商業保險方面,我們對 2026 年維持有紀律的定價策略,以確保適當報酬,而第一季表現也反映了這項聚焦。
As we look ahead to 2027 selling season, we are seeing strong employer interest, supported by a robust pipeline and early wins. Our integrated medical and pharmacy capabilities continue to resonate in the market. In individual ACA, we are seeing modestly stronger retention, particularly in bronze-tier plans where affordability remains critical.
展望 2027 年銷售季,我們看到雇主端的興趣強勁,並有穩健的商機管道與早期得標案例作為支撐。我們整合式的醫療與藥局能力持續在市場上引起共鳴。在個人 ACA 方面,我們看到續保率略有提升,尤其是在可負擔性仍至關重要的青銅級(bronze-tier)方案。
First-quarter results reflect pronounced seasonality given product mix, and the business remains on track toward a more sustainable financial profile. In Carelon, our risk-based solutions are delivering measurable value. Using AI and advanced analytics, we are identifying high-risk members earlier and engaging them through coordinated, whole-person care. That is driving higher medication adherence, fewer emergency room visits, and lower hospital readmissions. And it continues to support strong demand for our capabilities.
第一季結果因產品組合而呈現明顯季節性,但該業務仍按計畫朝更可持續的財務輪廓邁進。在 Carelon 方面,我們的風險承擔型解決方案正交付可衡量的價值。透過 AI 與先進分析,我們能更早辨識高風險會員,並以協調式、全人照護與其互動。這正帶動更高的用藥依從性、更少的急診就醫,以及更低的住院再入院率。同時也持續支撐市場對我們能力的強勁需求。
In summary, we are executing our strategy with discipline and clarity. Our actions are translating into measurable results: improving affordability, simplifying the healthcare experience, and strengthening financial performance. We are building momentum, and we are seeing that translate into more consistent performance across our businesses with strong visibility into the drivers of our results.
總結來說,我們正以紀律與清晰度執行策略。我們的行動正轉化為可衡量的成果:提升可負擔性、簡化醫療保健體驗,並強化財務表現。我們正在累積動能,並看到這股動能轉化為各項業務更一致的績效,同時對結果的驅動因素具備高度能見度。
Elevance Health was recently named to Fortune's 100 Best Companies to Work For list for the sixth consecutive year. We view that as a reflection of the strength of our culture and our people, and an important foundation as we improve execution and build greater consistency in our results. As we look ahead, we remain confident in our ability to deliver at least 12% adjusted EPS growth in 2027.
Elevance Health 最近連續第六年入選《財富》雜誌「100 家最佳雇主」榜單。我們認為這反映了我們文化與員工的強大實力,也是我們提升執行力並在業績表現上建立更高一致性的重要基礎。展望未來,我們仍有信心在 2027 年實現至少 12% 的調整後每股盈餘(EPS)成長。
Before I close, I want to recognize and thank our associates. Their commitment, resilience, and sense of purpose drive our progress, supporting our members, partnering with care providers, and advancing our mission every day.
在我結束之前,我想表揚並感謝我們的同仁。他們的投入、韌性與使命感推動我們持續前進,每天支持會員、與照護提供者合作,並推進我們的使命。
With that, I will turn the call over to Mark to review our first-quarter financial results and updated outlook.
接下來,我將把電話會議交給 Mark,請他回顧我們第一季的財務結果以及更新後的展望。
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Thank you, Gail, and good morning, everyone. Elevance Health reported first-quarter adjusted diluted earnings per share of $12.58, which exceeded our expectations. The strength in our operating results reflected favorable claims experience and seasonality in our individual ACA business.
謝謝你,Gail,各位早安。Elevance Health 第一季調整後稀釋每股盈餘為 12.58 美元,超出我們的預期。我們營運結果的強勁表現反映了有利的理賠經驗,以及我們個人 ACA 業務的季節性因素。
In addition, we recognized approximately $1 per share from non-recurring valuation adjustments within net investment income. We are raising our full-year 2026 adjusted diluted earnings per share guidance to at least $26.75 based on our first-quarter results, and we view the assumptions embedded in our outlook as appropriate and supported by current operating trends.
此外,我們在淨投資收益中認列了約每股 1 美元的一次性估值調整收益。基於第一季結果,我們將 2026 全年調整後稀釋每股盈餘指引上調至至少 26.75 美元;我們認為展望中所隱含的假設是適當的,並受到目前營運趨勢的支持。
Our confidence reflects the actions we are taking to manage cost trend and maintain expense discipline. Further, we are investing to scale AI across our enterprise, which will enable earlier identification of a member's health needs, guide them to more effective and affordable care, and reduce administrative complexity, strengthening both outcomes and long-term performance. In 2027, we expect to return to at least 12% adjusted EPS growth off of our revised 2026 earnings baseline of $25.75.
我們的信心來自於我們正在採取的行動,以管理成本趨勢並維持費用紀律。此外,我們正投資在全企業擴大 AI 規模,這將使我們能更早辨識會員的健康需求,引導其獲得更有效且更可負擔的照護,並降低行政複雜度,從而強化健康結果與長期績效。在 2027 年,我們預期將在修訂後的 2026 年每股盈餘基準 25.75 美元之上,恢復至少 12% 的調整後 EPS 成長。
Turning to our first-quarter results. We ended March with 45.4 million members, an increase of nearly 200,000 from year end, driven by growth in our commercial fee-based membership and higher enrollment in individual ACA. This was partly offset by anticipated declines in Medicare Advantage, employer group risk, and Medicaid. Operating revenue totaled $49.5 billion, up 1.5% year over year as higher premium yields were largely offset by lower health plan membership compared with the prior year.
接著看第一季結果。截至 3 月底,我們的會員數為 4,540 萬人,較年末增加近 20 萬人,主要由商業按費用計價(fee-based)會員成長以及個人 ACA 投保人數增加所帶動。部分增長被 Medicare Advantage、雇主團體風險(employer group risk)以及 Medicaid 的預期下滑所抵銷。營運收入合計 495 億美元,年增 1.5%;較高的保費收益率大致被相較去年較低的健康計畫會員數所抵銷。
Our consolidated benefit expense ratio was 86.8%. Medical costs were modestly better than we had assumed in our outlook, reflecting both favorable claims experience and the impact from actions we have taken to manage trend. These collectively contributed approximately two-thirds of our operating outperformance in the quarter. The remaining one-third reflected seasonality in our individual ACA business associated with higher membership in our bronze plans, which have benefit designs that typically defer a greater portion of plan costs into the second half of the year.
我們的合併給付費用率為 86.8%。醫療成本略優於我們在展望中的假設,反映了有利的理賠經驗,以及我們為管理趨勢所採取行動的影響。上述因素合計約貢獻本季營運超預期表現的三分之二。其餘三分之一則反映我們個人 ACA 業務的季節性因素,與我們青銅級(bronze)方案會員數較高有關;此類方案的給付設計通常會將較大比例的計畫成本遞延至下半年。
Our adjusted operating expense ratio was 10.5%, an improvement of 20 basis points year over year. While we continue to manage costs thoughtfully, the focus investments we're making in artificial intelligence and Carelon's clinical capabilities will improve how we operate, strengthen our earnings power, and better position the enterprise for long-term growth.
我們的調整後營運費用率為 10.5%,較去年同期改善 20 個基點。在我們持續審慎管理成本的同時,我們在人工智慧與 Carelon 臨床能力方面的重點投資,將改善我們的營運方式、強化獲利能力,並使企業在長期成長上具備更佳定位。
Before discussing our performance in greater detail, I want to briefly highlight two items recorded in the quarter that were excluded from adjusted earnings. First, we have initiated steps to submit risk adjustment data related to historical periods to CMS and are following the process established by the agency to bring this matter to resolution. We recorded an accrual of $935 million, representing our current best estimate of the identified potential exposure based on the information available today.
在更詳細討論我們的表現之前,我想先簡要說明本季入帳、但未納入調整後盈餘的兩項事項。第一,我們已啟動相關步驟,將與歷史期間相關的風險調整資料提交給 CMS,並依循該機構既定流程推動此事的解決。我們提列了 9.35 億美元的應計費用,代表基於目前可得資訊、對已識別潛在曝險的最佳估計。
While the final amount will be determined through the resolution process, we believe our accrual appropriately reflects this matter. Second, we recorded a $129 million charge related to business optimization. This reflects ongoing actions to simplify organizational structures and support accelerated decision-making.
雖然最終金額將透過解決流程確定,但我們認為此項應計已適當反映該事項。第二,我們認列了 1.29 億美元的費用,與業務優化相關。這反映了我們持續採取行動以簡化組織架構並支持加速決策。
Turning now to our businesses. Medicaid performance was slightly favorable to our expectations, benefiting from progress on the initiatives we have implemented to manage costs. We remain confident in our full-year operating margin outlook of approximately negative 1.75%, as our guidance maintains a prudent stance toward rate adequacy and trend development over the remainder of the year.
接著談我們的各項業務。Medicaid 的表現略優於我們的預期,受惠於我們已推行的成本管理措施所取得的進展。我們仍對全年約為負 1.75% 的營運利潤率展望有信心,因為我們的指引對於今年剩餘期間的費率充足性與趨勢發展維持審慎立場。
In Medicare, results were stronger than we anticipated, reflecting the impact of the portfolio actions we took for 2026. Those actions, including product repositioning and selective market exits, support improved performance, and we remain on track to achieve an operating margin of at least 2% this year. Commercial group developed as planned, consistent with the pricing discipline we outlined last quarter.
在 Medicare 方面,結果強於我們的預期,反映了我們為 2026 年所採取的投資組合調整行動的影響。這些行動(包括產品重新定位與選擇性退出部分市場)支持表現改善,我們仍按計畫在今年達成至少 2% 的營運利潤率。商業團體業務依計畫發展,與我們在上季所說明的定價紀律一致。
As employers focus on lowering healthcare costs, we are seeing stronger demand for our integrated whole health clinical programs and patient advocacy solutions. Individual ACA membership grew sequentially in the first quarter with a meaningful portion of the growth driven by our 2025 expansion states and more consumers selecting plan options at the bronze metal level. Our current view of membership effectuation indicates that we are on track to end the second quarter with approximately 1.2 million members ahead of our initial outlook.
隨著雇主專注於降低醫療保健成本,我們看到對於整合式全人健康臨床方案與病患倡議解決方案的需求更為強勁。第一季個人 ACA 會員數較前一季成長,其中相當部分的成長來自我們 2025 年擴張州(expansion states),以及更多消費者選擇青銅級(bronze metal level)的方案選項。我們目前對會員生效(effectuation)的觀察顯示,我們有望在第二季末的會員數較初始展望高出約 120 萬人。
However, given the unique market dynamics this year and a significant shift in product mix, it is still early to revise our full-year outlook for at least 900,000 members. Carelon's first-quarter operating gain declined modestly from the prior year, reflecting lower health plan membership and continued investment in the expansion of our risk-based capabilities, partially offset by improvements in specialty pharmacy in CareBridge.
然而,鑑於今年獨特的市場動態以及產品組合的顯著轉變,目前仍為時尚早,尚不宜修訂我們全年至少 90 萬名會員的展望。Carelon 第一季營運收益較去年略為下滑,反映健康計畫會員數較低,以及我們持續投資擴大風險承擔能力(risk-based capabilities);部分影響被 CareBridge 專科藥局業務的改善所抵銷。
These dynamics are consistent with how we are evolving the business, and we remain focused on advancing performance over time. Carelon is an important contributor to our enterprise performance and a key driver of our long-term growth strategy.
這些動態與我們推動業務演進的方向一致,我們仍專注於隨時間推進績效改善。Carelon 是我們企業整體表現的重要貢獻者,也是我們長期成長策略的關鍵驅動因素。
Now moving to the balance sheet and operating cash flow. Days in claims payable were 46.6 days, an increase of 5.3 days sequentially. Operating cash flow was $4.3 billion in the quarter, and we continue to expect full-year operating cash flow of at least $5.5 billion, inclusive of potential cash payments related to the CMS matter. In the quarter, we repurchased 3.7 million shares for $1.1 billion at an average price of just over $300 per share. Our capital deployment priorities reflect confidence in the durability of our business and its long-term earnings power, and we remain on track for at least $2.3 billion of share repurchases in 2026.
接著看資產負債表與營運現金流。應付理賠天數為 46.6 天,較前一季增加 5.3 天。本季營運現金流為 43 億美元;我們仍預期全年營運現金流至少 55 億美元,其中包含與 CMS 事項相關的潛在現金支付。本季我們以 11 億美元回購 370 萬股,平均回購價格為每股略高於 300 美元。我們的資本配置優先順序反映了我們對業務韌性及其長期獲利能力的信心;我們仍按計畫在 2026 年至少回購 23 億美元的股票。
We are pleased with a strong start to the year and are confident in our full-year outlook. Beyond the update to our 2026 earnings per share guidance, the principal operating elements of the framework we provided last quarter remain appropriate. With respect to seasonality, our expectations for the second quarter are largely unchanged, and we anticipate our second-quarter earnings per share to be approximately 23% of our revised full-year guidance.
我們對今年強勁的開局感到滿意,並對全年展望充滿信心。除更新 2026 年每股盈餘指引外,我們在上季提供的框架中,主要營運要素仍然適用。就季節性而言,我們對第二季的預期大致不變,並預期第二季每股盈餘約占修訂後全年指引的 23%。
With that, operator, please open the line for questions.
以上,接線員,請開放線路進行提問。
Operator
Operator
(Operator Instructions) AJ Rice, UBS.
(接線員指示) AJ Rice,瑞銀。
AJ Rice - Analyst
AJ Rice - Analyst
Hi, everybody, and thanks for the question. Maybe just we're well into the PBM selling season for 2027. And I guess we're gearing up for the commercial employer market selling season. Are you hearing anything different in terms of the amount of activity that you're seeing out there and the types of priorities that our employers are putting on engaging, anything they're emphasizing given AI, given a little uncertainty in the economy that you would call out that's different this year as we begin to move into the selling season?
大家好,謝謝這個問題。也許我們已經進入 2027 年 PBM 的銷售旺季。我想我們也正在為商業雇主市場的銷售季做準備。就你們在外面看到的活動量,以及雇主在參與時所設定的優先事項而言,你們是否聽到任何不同之處?在 AI、以及經濟略有不確定性的背景下,他們是否有任何今年特別強調、值得點出的不同之處,因為我們正開始進入銷售季?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thanks for the question, AJ. And I think it's a great one to start the call. Let me start with the commercial selling season, and then I'll ask Mark to comment on the PBM. But in terms of the national accounts season, in particular, where we see early -- I think, early interest by employers, as I think I shared in my remarks, we're off to a really strong start. We've got some early wins.
AJ,謝謝你的提問。我認為這是一個很適合用來開場的問題。我先從商業銷售季談起,接著我會請 Mark 也評論一下 PBM。就全國性大客戶(national accounts)的銷售季而言,特別是我們看到雇主的早期——我想是早期興趣——正如我在發言中分享的,我們開局非常強勁。我們已經拿下一些早期勝利。
What we're hearing from our national account employers is they're very focused on affordability. AI is important in terms of the consumer experience. As you know, we've got two core goals: reduce the cost of healthcare for them and improve the experience, and we've been investing heavily in ensuring that those capabilities choke through. So from an employer perspective, we just hosted our national account group, and we had most of our clients in and they shared with us, I think, a lot of satisfaction.
我們從全國性大客戶雇主那裡聽到的是,他們非常聚焦在可負擔性。AI 在消費者體驗方面也很重要。如你所知,我們有兩個核心目標:為他們降低醫療成本並改善體驗,而我們也一直大力投資,確保這些能力能夠真正落地並發揮作用。因此,從雇主角度來看,我們剛接待了全國性大客戶團隊,絕大多數客戶都到場,並與我們分享了我認為相當高的滿意度。
We had a very strong '26 selling year. But also '27, we have a very strong pipeline, almost a record level for '27. We're pretty enthusiastic about how our assets are resonating. The other thing that we're starting to see is, again, continued consolidation from clients. We've had a record of taking clients who have multiple carriers and consolidating some single carrier under us. And that theme is continuing.
我們在 2026 年的銷售年度非常強勁。而且在 2027 年,我們也有非常強的案源管道,幾乎是 2027 年的創紀錄水準。我們對於我們的資產如何引起共鳴感到相當振奮。另外一點我們開始看到的是,客戶端持續的整併。我們過去有一個紀錄:把原本使用多家承保商(carriers)的客戶,整併為由我們單一承保。而這個趨勢仍在延續。
So we're very optimistic. But overall, the season, I would say, very focused on affordability given what's going on in the economy, but also very focused on experience and wanting to ensure simplicity that there's real value pulling through for the commercial group. But let me ask Mark to comment on the PBM side as well.
所以我們非常樂觀。但整體而言,我會說本季非常聚焦在可負擔性,考量到目前經濟情勢;同時也非常重視體驗,並希望確保簡化流程,讓商業團體客群能真正感受到價值的落地。不過我也請 Mark 一併談談 PBM 端的情況。
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Yeah. Thanks, AJ. CarelonRx delivered a strong ASO selling season for 2026. So we had several national account wins. We also had improved win rates across both the middle market and large group. And that performance here really reflects growing demand for a more integrated medical pharmacy model and for some of the differentiated value that CarelonRx is able to bring to employers and our health plan partners.
是的。AJ,謝謝。CarelonRx 在 2026 年的 ASO 銷售季表現強勁。因此我們拿下了數個全國性大客戶的勝利。我們在中型市場與大型團體兩個區隔的得標率也有所提升。而這樣的表現確實反映出市場對更整合的醫療—藥局(medical pharmacy)模式的需求正在增加,以及 CarelonRx 能為雇主與我們的健康保險計畫合作夥伴帶來的一些差異化價值。
I'd say sales momentum remains strong. We have seen total sales to date running ahead of plan including two marquee national wins. And that really does highlight our ability to compete upmarket successfully for large, sophisticated clients. We've also seen good renewal activity, especially as we enter this active phase of some of the client strategy discussions.
我會說銷售動能仍然強勁。我們看到截至目前的總銷售額高於計畫,其中包括兩個指標性的全國性勝利。這也確實凸顯了我們有能力在高端市場成功競爭,服務大型且成熟的客戶。我們也看到良好的續約活動,特別是當我們進入一些客戶策略討論的活躍階段之際。
On the commercial side, good penetration across that book, good cross-selling of pharmacy into our existing fee-based relationships that obviously remains an important lever for us. And the reason this opportunity is real is that it is producing measurable results. And maybe just to give you two examples here.
在商業端,我們在該業務組合中的滲透率良好,也把藥局服務交叉銷售到我們既有的按費用計價(fee-based)合作關係中,這顯然仍是我們的重要槓桿。而之所以說這個機會是真實存在的,是因為它正在產生可衡量的成果。我也許用兩個例子來說明。
We have seen for clients that do have that aligned medical pharmacy benefit savings upwards of $100 per member per month as well as significantly fewer ER visits, as well as a reduction in some of the high-cost specialty drug administration. So in short, as we look forward to 2027, our confidence is really grounded in that pipeline momentum and the demonstrated value that we bring.
我們看到,對於確實採用這種醫療與藥局福利對齊的客戶,每位會員每月(PMPM)的節省可超過 100 美元,同時急診(ER)就診次數也顯著減少,另外也降低了一些高成本專科藥物的給藥(administration)費用。總之,展望 2027 年,我們的信心確實建立在這股案源管道動能,以及我們所帶來的已被驗證的價值之上。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Yes. Thanks, Mark, and thanks, AJ. I think you heard from both of us, we feel really well positioned in -- for national accounts as well as for employer groups. So next question please.
是的。謝謝你,Mark,也謝謝你,AJ。我想你從我們兩位的回答中都聽得出來,無論是全國性大客戶或雇主團體客群,我們都覺得自身處於非常有利的位置。所以下一題,請。
Operator
Operator
Stephen Baxter, Wells Fargo.
Stephen Baxter,富國銀行。
Stephen Baxter - Analyst
Stephen Baxter - Analyst
I was hoping you could expand a little bit on the cost strain comments. Obviously, it seems like you're seeing some level of moderation in Medicare and are confident enough at this stage to identify that. And then on Medicaid, on the other hand, seems to be much more consistent with what you've been talking about recently. Maybe help us try to understand the differentiation that you're seeing there and what's driving that at this stage.
我希望你能再多談一點關於成本壓力(cost strain)的評論。顯然,看起來你們在 Medicare 端看到某種程度的趨緩,而且在這個階段你們也有足夠信心指出這一點。但另一方面,Medicaid 似乎更符合你們最近一直在談的情況。也許可以幫助我們理解你們在兩者之間看到的差異,以及在這個階段是什麼在驅動這些差異?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thanks for the question, Stephen. Maybe it would be helpful to sort of take a step back in total, because I think, as we said, we're really pleased with the strong start to this year. At a high level, cost trend is tracking in line with the expectations, and that's consistent with the stronger performance that we delivered in the quarter. But I think what's really important, as you look through our results, it's not one driver or one single item.
Stephen,謝謝你的提問。也許先從整體退一步看會比較有幫助,因為我想正如我們所說,我們對今年強勁的開局感到非常滿意。從高層次來看,成本趨勢(cost trend)與我們的預期一致,這也與我們在本季交出的較強表現相符。但我認為,當你細看我們的結果時,真正重要的是:這不是單一驅動因素或單一項目所造成的。
What we saw going into this year is solid execution across our entire enterprise, and that's what supports our full-year adjusted EPS outlook guide of $26.75. And more importantly, I think it gives us much more confidence into the trajectory, not only this year but into '27. From a cost standpoint, I just want to point out some of the actions that we've taken are beginning to show through.
我們在進入今年時看到的是,整個企業範圍內都有扎實的執行力,而這正是支撐我們全年調整後 EPS 指引 26.75 美元的基礎。更重要的是,我認為這也讓我們對於趨勢軌跡更有信心,不僅是今年,也包括 2027 年。從成本角度來看,我也想指出,我們採取的一些行動正開始反映在成果上。
So as you think about earlier using data to find out where the outliers are, utilization management, stronger payment integrity, for example, and an area that I think is really important is better site of care optimization, where we've been very focused on that. So overall, we see the businesses are performing in line. And in some cases, as Mark shared, they're ahead of assumptions. So we've embedded, we think, very prudent assumptions in our outlook, I think, and that speaks to the resilience of the portfolio.
因此,回到先前提到運用數據找出異常值(outliers)、利用管理(utilization management)、更強的支付完整性(payment integrity)等;另外我認為非常重要的一個領域是更好的就醫地點最佳化(site of care optimization),我們在這方面一直非常聚焦。總體而言,我們看到各項業務的表現符合預期。而在某些情況下,如 Mark 所分享的,甚至優於原先假設。因此我們在展望中納入了我們認為非常審慎的假設,而這也反映出投資組合的韌性。
But I also want to, I guess, continue to say we're going to stay disciplined in how we view the balance of the year, and we're not relying on different trend environment to support the guide. So we're going to continue to scale what we're doing. But bottom line, I think it's important that our business, we feel, is performing well, and those actions are going to continue to gain traction throughout the year, and that reinforces our confidence. So thanks very much for the question.
但我也想繼續強調,我們會在看待今年剩餘期間時保持紀律,我們並不是依賴不同的趨勢環境來支撐這份指引。所以我們會持續擴大我們正在做的事情。但歸根結底,我認為重要的是,我們覺得業務表現良好,而這些行動將在全年持續取得更大的成效並加速落地,這也強化了我們的信心。非常感謝你的提問。
Next question, please.
下一題,請。
Operator
Operator
Justin Lake, Wolfe Research.
Justin Lake,Wolfe Research。
Justin Lake - Analyst
Justin Lake - Analyst
Your guidance assumed a conservative view of Medicaid membership declines, I think, in the high single-digit range for the year. And I noticed for the quarter, Medicaid membership looks like it was down about 1.5% ex the growth in Indiana. So I'm curious what you're seeing here in terms of membership mix?
你們的指引似乎採用了對 Medicaid 會員數下滑較保守的看法,我想全年大約是高個位數百分比的下降。而我注意到就本季而言,若排除印第安納州的成長,Medicaid 會員數看起來大約下降了 1.5%。所以我想了解你們在會員結構(membership mix)方面目前看到的是什麼?
Specifically, are you seeing membership declines heavier among lower-utilizing members, potentially pressuring the risk pool? And can you remind us what you've built in for acuity pressure within your Medicaid margin guidance?
具體來說,您是否看到會員下滑主要集中在使用率較低的會員身上,可能因此對風險池造成壓力?另外,能否提醒我們,在您對 Medicaid 利潤率指引中,已納入多少病情嚴重度(acuity)上升的壓力?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Mark?
Mark?
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Thanks very much for the question, Justin. We remain quite comfortable with our Medicaid membership guidance range that we provided for 2026, which just as a reminder, reflects a high-single-digit percentage decline driven by ongoing eligibility reverifications and disenrollment activity. At this point, we do expect to finish the year towards the higher end of that range, and that reflects both the prudence embedded in our original outlook and the way that the state reverification activity has unfolded so far this year.
Justin,謝謝你的提問。我們對於先前提供的 2026 年 Medicaid 會員數指引區間仍然相當有信心;提醒一下,該指引反映的是在持續的資格重新核驗與退保活動推動下,會員數將出現高個位數百分比的下滑。就目前而言,我們預期今年結束時會落在該區間的較高端,這同時反映了我們原先展望中所內含的審慎假設,以及今年迄今各州重新核驗活動的實際進展。
Overall, what we've seen to date has been broadly consistent with our expectations. I would say timing has been modestly more favorable than what we originally assumed. And then finally, I would say our full-year guidance does assume that greater membership pressure from reverifications over the balance of the year versus what we saw in the first quarter. And that simply reflects that range of potential state actions, some of the uncertainty around the implementation of the timing of those six-month eligibility periods, and then overall enrollment-related pressures as the year progresses.
整體而言,我們迄今看到的情況大致符合我們的預期。我會說在時點上比我們原先假設的略為有利。最後,我也會說,我們的全年指引確實假設在今年剩餘期間,因重新核驗帶來的會員壓力會高於第一季所見。這只是反映了各州可能採取行動的範圍、對於六個月資格期間時點落實的不確定性,以及隨著年度推進整體與投保相關的壓力。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Yeah. Thanks, Mark. And also just to sort of bring it together for you, Justin, I mean, this is aligning similar to what we put in our guidance. And we do, as we've shared before, I think this is the trough year. And we continue to believe that given what we're seeing in the business.
是的。謝謝,Mark。另外,Justin,為了把整體脈絡串起來,我的意思是,這與我們在指引中所納入的假設一致。而且我們也如先前分享過的,我認為今年是谷底的一年。基於我們在業務中看到的情況,我們仍然相信這一點。
Next question, please.
請下一題。
Operator
Operator
Andrew Mok, Barclays.
Barclays 的 Andrew Mok。
Andrew Mok - Analyst
Andrew Mok - Analyst
I wanted to follow up on the employer side and the affordability discussion. Can you help us understand what you're seeing in terms of consumer behavior in response to reset deductibles? And relatedly, have you observed any impact from higher gas prices or broader macro pressures on healthcare utilization?
我想就雇主端與可負擔性(affordability)的討論追問一下。能否協助我們理解,您們看到消費者在面對自付額重置(reset deductibles)時的行為反應是什麼?另外,您們是否觀察到油價上升或更廣泛的總體經濟壓力,對醫療使用量造成任何影響?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
I'll ask Morgan to share his perspective. Morgan?
我請 Morgan 來分享他的觀點。Morgan?
Morgan Kendrick - Executive Vice President and President, Commercial and Specialty Health Benefits
Morgan Kendrick - Executive Vice President and President, Commercial and Specialty Health Benefits
Yeah, Andrew, thanks for the question. I will tell you the market is completely aligned with our strategy of reducing the cost of healthcare and improving the experience of the consumer, making it simpler. I think that's the biggest thing that I hear that it's overly complex, burdensome for the consumers to actually seek care, go through treatments, things of that nature.
是的,Andrew,謝謝你的問題。我可以告訴你,市場與我們降低醫療成本、改善消費者體驗並讓流程更簡單的策略完全一致。我聽到最多的是:整體過於複雜,對消費者而言負擔很重,導致他們在實際就醫、接受治療等方面都變得困難。
That's where we're working together to solve those. That is exactly where -- and I think that's why, as Gail mentioned earlier, we had such a strong season upmarket, and that also permeates into our down-level business as well. So if we think about our local geographies and national, all of this is focused around affordability and simplicity.
這正是我們共同努力要解決的地方。也正因如此——我想這也是 Gail 先前提到的原因——我們在高端市場(upmarket)有非常強勁的一季,而這也同樣滲透到我們較低層級(down-level)的業務中。因此,無論是我們的在地市場或全國市場,所有重點都圍繞在可負擔性與簡化。
Beyond that, it's just a little things around the edges are just about accentuating both of those. That said, we do see a shift in way of funding. So of course, as you go further up, it's all self-funded business. It's a fee-based business. If you look at the down market, it's about 50-50 between risk-based and fee-based. Nonetheless, people want to know that we're focused on the right things.
除此之外,其他只是一些邊際上的小事,目的在於進一步強化這兩點。話雖如此,我們確實看到資金安排方式的轉變。當然,越往高端走,幾乎都是自籌資金(self-funded)業務。那是一種以費用為基礎(fee-based)的業務。如果看較低端市場,大約是風險承擔(risk-based)與費用制(fee-based)各半。不過無論如何,大家都希望知道我們把焦點放在正確的事情上。
And as Gail mentioned, we listen to the markets, and the markets tell us quite carefully and honestly that it's all around affordability. How are we leveraging the unit cost position that we have and then how are we medically managing that to the point that is driving their trends down consistently.
而且如 Gail 所說,我們傾聽市場,市場也非常謹慎且坦率地告訴我們,一切都圍繞在可負擔性。我們如何運用我們所具備的單位成本優勢,並且如何透過醫療管理把它落實到能持續把他們的趨勢(trend)壓低。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Yes. Thanks, Morgan. Maybe a little bit on the ACA, Mark, just in terms of what we're seeing in consumer behavior there.
是的。謝謝,Morgan。Mark,也許你可以再談一下 ACA,就我們在那邊看到的消費者行為而言。
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
No, absolutely. So I'd say broadly, Andrew, consumer shopping behavior in the ACA market has been in line with our expectations. The biggest difference here versus our initial view is that shift towards bronze plans has been more pronounced and is a positive for us in certain markets. And that dynamic clearly makes sense in the current environment because obviously, subsidies are tied to that benchmark silver plan.
當然可以。Andrew,我會說整體而言,ACA 市場的消費者比價/選購行為符合我們的預期。相較於我們最初的看法,最大的差異是:轉向青銅方案(bronze plans)的趨勢更為明顯,且在某些市場對我們是正面的。而在目前環境下,這個動態顯然合理,因為補貼是與基準白銀方案(benchmark silver plan)連動的。
And as benchmark premiums move higher in 2026, those bronze options became more affordable on that net of subsidy basis for consumers. So we feel pretty good about our positioning in ACA.
隨著 2026 年基準保費上升,對消費者而言,在扣除補貼後(net of subsidy)的基礎上,青銅選項變得更可負擔。因此我們對於在 ACA 的布局感覺相當不錯。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Next question, please.
請下一題。
Operator
Operator
Lisa Gill, JPMorgan.
JPMorgan 的 Lisa Gill。
Lisa Gill - Analyst
Lisa Gill - Analyst
I want to ask a question around Carelon and CarelonRx. When I look at the margin in the quarter, it came in below our expectations. You reiterated the guidance for the year. Can you talk about the progression of getting that margin back when we think about Carelon specifically and then within that, CarelonRx?
我想問一個關於 Carelon 與 CarelonRx 的問題。當我看本季的利潤率時,結果低於我們的預期。你們重申了全年指引。能否談談利潤率回升的進程:先就 Carelon 本身,然後在其中再談 CarelonRx?
And then secondly, any comments around recent legislation, whether we think about what's passed on the federal level and any impact to your business on the PBM side or the potential of what's been proposed, for example, in the state of Tennessee, any impact on the PBM business?
第二,對於近期立法有沒有任何評論:不論是聯邦層級已通過的法案,以及對你們 PBM 端業務的任何影響;或是例如田納西州所提出的提案,對 PBM 業務是否可能造成影響?
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Lisa, thanks very much for the question. Let me start with the performance first in Rx. So I would say performance here was very much in line with our expectations in the quarter. Revenue growth was driven by strong revenue per script and continued momentum in the external business, particularly in the ASO space, and that was partially offset by lower script volume from the affiliated health plan membership.
Lisa,謝謝你的提問。我先從 Rx 的表現談起。我會說本季的表現非常符合我們的預期。營收成長主要由每張處方(per script)的強勁營收,以及外部業務(尤其是 ASO 領域)的持續動能所帶動;但部分被來自關聯健康計畫會員的處方量較低所抵銷。
On margin, to your question, the key point here is that the first-quarter performance was very much in line with our expectations, and it's fully consistent with our full-year guide for that mid-5% margin range. I'd say the quarter itself reflected very normal seasonality in the PBM business, along with expected mix of growth and the current earnings cadence across the platform. Though we did see some improvements in specialty and home dispensing. So that obviously helped overall performance in the quarter.
至於利潤率,你的問題重點在於:第一季的表現非常符合我們的預期,且與我們全年指引中約 5% 中段的利潤率區間完全一致。我會說本季反映了 PBM 業務非常正常的季節性,以及我們預期的成長組合(mix)與平台目前的獲利節奏。不過我們確實看到專科藥與居家配藥(home dispensing)方面的一些改善。因此這顯然有助於本季的整體表現。
But if you step back, I'd say, from an Rx perspective, revenue and margin, very much in line with what we expected. On your point on the regulatory for a minute, I think the direction of travel here is pretty clear. We have seen recent federal actions moving that PBM market towards greater transparency, stronger reporting and I think ultimately closer alignment between PBMs and their clients.
但如果你拉遠一點看,我會說就 Rx 而言,無論營收或利潤率,都非常符合我們的預期。至於你提到的監管,我認為整體走向相當明確。我們已看到近期聯邦層級的行動,正推動 PBM 市場走向更高的透明度、更強的申報/揭露要求,並且我認為最終會讓 PBM 與其客戶之間的利益更一致。
And so for CarelonRx, I would say that direction of travel is fully consistent with the model that we are building. We already offer clients flexibility in how they engage with us, and that includes rebate pass-throughs as well as transparent fee-based arrangements. And more importantly, I'd say our strategy here in Rx is not dependent upon any single economic mechanism. It really is built around that integrated medical and pharmacy management and a focus on total cost of care.
因此對 CarelonRx 而言,我會說這個走向與我們正在打造的模式完全一致。我們已提供客戶在與我們合作方式上的彈性,包括回扣轉付(rebate pass-through)以及透明的費用制安排。更重要的是,我會說我們在 Rx 的策略並不依賴任何單一的經濟機制。它真正的核心是整合式的醫療與藥事管理,並聚焦於整體照護成本(total cost of care)。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thank you, Mark. Next question, please.
謝謝你,Mark。請下一題。
Operator
Operator
Lance Wilkes, Bernstein.
Bernstein 的 Lance Wilkes。
Lance Wilkes - Analyst
Lance Wilkes - Analyst
Got a question on employer and in particular, the progress you're making on the second Blue bid sort of opportunity out there. Maybe if you could just remind us of the '26 experience you had in sales there. But then if you could just talk a little about the value proposition you're selling, sort of the target clients who are going to be open to this and what pipeline looks like for '27? And as part of that, if there's any detail on the type of Carelon Services that some of those people would be picking up more likely?
我有一個關於雇主端的問題,特別是你們在第二個 Blue bid 這類機會上的進展。也許你可以先提醒我們一下你們在 '26 年在那邊銷售端的經驗。接著也請談談你們正在銷售的價值主張、哪些目標客戶會對此持開放態度,以及 '27 年的案源管線看起來如何?另外,若方便的話,能否提供一些細節:這些客戶更可能會採用哪些類型的 Carelon Services?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thanks, Lance. I'll have Morgan address your questions.
謝謝你,Lance。我請 Morgan 來回應你的問題。
Morgan Kendrick - Executive Vice President and President, Commercial and Specialty Health Benefits
Morgan Kendrick - Executive Vice President and President, Commercial and Specialty Health Benefits
Lance, thanks for the question. Regarding the -- what we're seeing in the national space, with second Blue bid, it was quite -- last year, as you know, was the very first year we did it. It was very lucrative for the business. We had lots -- we had probably 40 more additional opportunities that came through. And so it was there.
Lance,謝謝你的提問。關於——我們在全國性市場看到的第二個 Blue bid,確實——如你所知,去年是我們第一次做。對業務而言非常有利可圖。我們有很多——大概多了 40 個額外機會進來。所以確實存在。
We're still seeing that again in year two, but nonetheless, not quite as high. We've got roughly 2 million members in queue. A couple of those are second Blue bid, but the overwhelming majority is just business in the market coming from other places. So it's -- to me, it's -- the assets speak for themselves, and that's exactly what the markets are telling us.
我們在第二年仍然再次看到這樣的情況,但不過,規模沒有那麼高。目前大約有 200 萬名會員在排隊中。其中有幾個是第二個 Blue bid,但絕大多數只是市場上來自其他來源的業務。所以——對我來說——資產本身就能說明一切,而市場也正是這樣告訴我們的。
The renewal numbers that we've seen in our national business are nearly 100%. It's like 99.3%. So you think about -- these are organizations that don't move very often. They like what they're getting, they like and they keep it.
我們在全國性業務看到的續約率幾乎是 100%。大概是 99.3%。所以你想想——這些組織不會經常更換。他們喜歡自己得到的服務,他們喜歡,然後就會持續保留。
To the point around Carelon, when I think about what they're looking for with Carelon, they're looking for various solutions around medical conditions, MSK, diabetes, things of that nature to work directly in their population where it may be skewed in those areas, and we can solve for it with them. And also, as Mark indicated, pharmacy. Last year was one of the largest years we've had around integrated Rx in the upper end of the market. We do expect that to play in, but it was really, really strong last year, and we expect it to be slightly dampened this year.
談到 Carelon,我認為他們在 Carelon 方面尋求的是各種針對醫療狀況的解決方案,例如肌肉骨骼(MSK)、糖尿病等,能直接在其族群中運作——若他們的人口結構在這些領域偏高——我們就能與他們一起解決。另外,如 Mark 所提到的,還有藥局(pharmacy)。去年是我們在高端市場整合式處方(integrated Rx)表現最強的一年之一。我們確實預期這仍會發揮作用,但去年真的非常強,今年我們預期會略為降溫。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thank you, Morgan. Next question, please.
謝謝你,Morgan。請下一題。
Operator
Operator
Ann Hynes, Mizuho Securities.
Mizuho Securities 的 Ann Hynes。
Ann Hynes - Analyst
Ann Hynes - Analyst
I know you said Medicaid margins were tracking better than your expectations and what's embedded in guidance. Can you actually tell what Q -- tell us what Q1 results were? And can you also remind us what your rate increases are for 2026 [as in] guidance? And have there been any positive updates since the last report?
我知道你們說 Medicaid 利潤率的走勢優於你們的預期,也優於指引中所內含的假設。你們能否實際告訴我們 Q——也就是 Q1 的結果是多少?另外也請提醒我們,2026 年指引中假設的費率調升幅度是多少?自上次報告以來,有沒有任何正面的更新?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Mark, I'll ask you to start and then Felicia to give some more comments.
Mark,我先請你開頭,然後請 Felicia 再補充一些評論。
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Ann, thanks very much for the question. So from a trend perspective, I would say first quarter was slightly ahead of our expectations. That reflected the favorable claims development. That said, underlying cost trend does remain elevated. The first-quarter trend is consistent with our full-year outlook.
Ann,非常感謝你的提問。就趨勢而言,我會說第一季略優於我們的預期。這反映了理賠發展(claims development)較為有利。話雖如此,基礎成本趨勢仍然偏高。第一季的趨勢與我們對全年展望一致。
And we do continue to contemplate Medicaid trend at the high end of that mid-single-digit guidance range that we provided. So as you think about margins, to your question for the first quarter, certainly, on a sequential basis, we did see an expected deterioration in the first quarter, meaning coming in exactly as we anticipated. And so for the full year, we're continuing to be very comfortable with our guide of minus 1.75% operating margin.
而且我們仍然預期 Medicaid 的趨勢會落在我們所提供的「中個位數」指引區間的高端。所以談到利潤率、回到你對第一季的問題,當然,按季來看,我們確實看到第一季出現預期中的惡化,也就是結果完全符合我們的預期。因此就全年而言,我們仍然非常有信心維持我們的指引:營業利潤率為 -1.75%。
Felicia Norwood - Executive Vice President and President, Government Health Benefits
Felicia Norwood - Executive Vice President and President, Government Health Benefits
Good morning, Ann, and thank you for the question. In terms of our Medicaid rates, our Medicaid rates for the first quarter, which means through April, are right in line with our expectations. The rates absolutely are coming in close to the mid-single-digit range. At the end of the day, however, that remains slightly below the trend that we continue to see in the business.
Ann,早安,謝謝你的提問。就我們的 Medicaid 費率而言,第一季(也就是截至 4 月)的 Medicaid 費率與我們的預期一致。費率確實接近中個位數的區間。不過歸根結底,這仍略低於我們在業務中持續看到的趨勢水準。
So we are going to continue to work very constructively with our state partners around closing that rate to trend gap. Overall, I will tell you that those conversations continue to be very constructive. We provide regular information to our states in terms of our performance, and we look forward to continuing to make the improvements that we expect to see in the Medicaid rates over time.
因此,我們將持續以非常具建設性的方式,與各州合作夥伴一起努力縮小「費率與趨勢」之間的落差。整體而言,我可以告訴你,這些對話仍然非常具建設性。我們會定期向各州提供我們績效表現的資訊,也期待持續推動改善,讓 Medicaid 費率隨時間推進達到我們預期的提升。
But through the first quarter, certainly right in line with the expectations, and we've already started to work with our states around July rates, although it's still early in terms of a view of July, but the continued progress that we're making is expected to really continue throughout the rest of the year. So thank you very much for the question.
但截至第一季,確實完全符合預期;而且我們也已經開始就 7 月費率與各州展開合作,雖然就 7 月的觀察仍然偏早,但我們持續取得的進展,預期會在今年剩餘期間持續推進。所以非常感謝你的提問。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Next question, please.
請下一題。
Operator
Operator
Scott Fidel, Goldman Sachs.
Goldman Sachs 的 Scott Fidel。
Scott Fidel - Analyst
Scott Fidel - Analyst
I was hoping if you could maybe expand on just giving us an update on the risk-based management programs that you've been deploying in Carelon Services. Maybe just talk about the overall scope of how those programs have been expanding and the -- and basically sort of the actions within the operating model that you have to sort of protect against sort of upside risk on medical cost trend? And then also if you could just talk about the investments that you called out in the quarter also related to that line of business?
我想請你們再多談一些,更新一下你們在 Carelon Services 部署的風險基礎管理(risk-based management)方案。也許談談這些方案擴張的整體範圍,以及——基本上——在營運模式中你們採取了哪些行動,以防範醫療成本趨勢上行所帶來的風險?另外也請談談你們在本季提到、同樣與該業務線相關的投資。
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Scott, thanks very much for the question this morning. I think let me start off by saying that we are taking a very disciplined approach to how we manage risk in Carelon Services. And specifically, we're very intentional about where we take risk in the business, how we price for it and then ultimately, how we balance that exposure across our Medicare, Medicaid, and commercial businesses with a mix of either sub-capitated full risk or [really] fee-based offerings.
Scott,非常感謝你今天早上的提問。我想先說,我們在 Carelon Services 的風險管理上採取非常嚴謹自律的方法。具體而言,我們非常有意識地決定在業務中哪些地方承擔風險、如何為其定價,並且最終如何在 Medicare、Medicaid 與商業保險業務之間平衡這些曝險,透過次人頭(sub-capitated)的全風險模式或是(實際上)以費用為基礎的服務組合來搭配。
One of the real advantages in Carelon here is that we can use our affiliated health plan membership as a proving ground to launch and scale capabilities quickly. For example, we started our risk-based oncology solution in commercial. We expanded it into Medicare. And then we plan to move it into Medicaid in the latter half of this year.
Carelon 在這裡的一個真正優勢是,我們可以利用關聯健康保險計畫的會員作為試驗場,快速推出並擴大各項能力。例如,我們先在商業保險推出以風險為基礎的腫瘤(oncology)解決方案。我們把它擴展到 Medicare。然後我們計畫在今年下半年把它導入 Medicaid。
And we followed a similar path for post-acute and more recently in BH as well. So a lot happening in that space. At the same time, obviously, as we continue to grow the risk-based side of Carelon Services, the segment is going to reflect some of that normal mix and timing dynamics. And I think that's the heart of your question. And that really comes with our scaling of these capabilities.
而在急性後期照護(post-acute)以及最近在行為健康(BH)方面,我們也走了類似的路徑。所以那個領域有很多事情正在發生。同時,顯然,隨著我們持續擴大 Carelon Services 風險基礎業務的一端,該事業部門也會反映一些正常的組合與時點動態。我想這就是你問題的核心。而這確實會伴隨我們對這些能力的規模化擴張。
Just to point out, low affiliated health plan membership does remain a headwind across several of the offerings this year. And of course, some of the newer risk-based programs will have a different earnings cadence as they progress.
只是想指出,今年在多項產品中,附屬健康計畫(affiliated health plan)會員數偏低仍然是一項逆風。當然,一些較新的風險承擔型(risk-based)方案在推進過程中,獲利節奏也會有所不同。
And a couple of quick examples here before I leave at least this question. Risk-based oncology program, we started in 2024. We expanded in '25. Post-acute started in Medicare, we've deployed commercial. And then BH is the one that we've recently launched with some serious mental illness in the Medicaid population.
在我至少結束這個問題之前,先舉幾個簡單例子。風險承擔型腫瘤(oncology)方案,我們在 2024 年啟動。我們在 2025 年擴大規模。急性後期照護(post-acute)先從 Medicare 開始,我們也已部署到商業保險。然後 BH 是我們最近推出的,針對 Medicaid 人口中嚴重精神疾病(serious mental illness)族群的方案。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thank you. Next question, please.
謝謝。請下一題。
Operator
Operator
Ryan Langston, TD Cowen.
Ryan Langston,TD Cowen。
Ryan Langston - Analyst
Ryan Langston - Analyst
I appreciate you sizing the settlement potential CMS. I guess can you give us a sense on how those conversations are progressing? And I'd be interested if you could help us frame sort of how you arrived at that $935 million figure?
感謝你們量化了與 CMS 和解的潛在金額。我想請問你們能否談談這些對話目前進展如何?另外也想請你們協助我們理解,你們是如何推導出 9.35 億美元這個數字的?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Sure. Let me like provide you sort of a comprehensive view of how this works. Let me start with the accrual. First, the $935 million accrual that we recorded in the first quarter reflects our current best estimate of the probable exposure that is associated with this historical matter. And that's based on the information that we have today as well as our engagement with CMS.
當然。我來提供一個較完整的說明,讓大家了解這是怎麼運作的。我先從應計(accrual)談起。首先,我們在第一季認列的 9.35 億美元應計,反映的是我們目前對於這項歷史事項相關「可能」曝險(probable exposure)的最佳估計。這是基於我們目前掌握的資訊,以及我們與 CMS 的互動所做出的判斷。
I think it's important too, as you think about it, this relates to historical payment disputes that involves the interpretation of the risk adjustment policy during that period in question. And actually, really importantly, I think everyone -- to remind everyone, it's not about how we operate the business today, and it doesn't change the confidence, as I shared in my comments, about the integrity of our current risk adjustment practices, our compliance, or our governance.
我也認為很重要的是,這件事涉及的是歷史付款爭議,爭點在於當時期間對風險調整(risk adjustment)政策的解讀。而且非常重要的是——提醒大家——這不是關於我們今天如何營運業務,也不會改變我在評論中所分享的信心:也就是我們目前風險調整作法的完整性、合規(compliance)或治理(governance)。
But in terms of where we're going, since receiving the notice from CMS in February, we've moved very quickly to engage directly and quite constructively with the agency on this matter. And those discussions have given us much better clarity both on process and on the path to resolution. So I want to be clear about that. We are working through the process that CMS has outlined to address those issues raised.
至於我們接下來的方向,自從 2 月收到 CMS 的通知後,我們非常迅速地與該機構就此事直接且相當具建設性地展開溝通。這些討論讓我們在流程以及解決路徑上都獲得更清楚的掌握。所以我想把這點講清楚。我們正在依照 CMS 所提出的流程,處理所提出的相關問題。
And CMS has updated because of the compliance time frame, which you want to share and as we work through that process and under the current timeline, we have through July 31 to meet all of those compliance requirements. Certainly, we appreciate the extension of that time frame because it reflects, I think, the complexity of the work required to complete this.
另外,CMS 也因為合規時程(compliance time frame)而更新了期限;在我們依該流程推進、且依目前時程之下,我們有到 7 月 31 日的時間來滿足所有合規要求。我們當然感謝這個期限的延長,因為我認為這也反映了完成這項工作所需的複雜度。
That said, based on the steps that CMS has prescribed and the current timeline, which I've shared, we believe and expect that if we complete those steps that the sanctions will not go into effect. So I also want to share that. But again, we're working very constructively with the agency and feel that we're moving towards resolution of the issue. So thank you for the question.
話雖如此,基於 CMS 所規定的步驟以及我剛分享的目前時程,我們相信並預期,只要我們完成這些步驟,制裁(sanctions)就不會生效。我也想分享這一點。但再次強調,我們正以非常具建設性的方式與該機構合作,並且覺得我們正朝著解決此議題的方向前進。謝謝你的提問。
Next question, please.
請下一題。
Operator
Operator
Elizabeth Anderson, Evercore ISI.
Elizabeth Anderson,Evercore ISI。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Thanks so much for the question. Just appreciate the comments about the two-thirds of the outperformance is favorable claims and sort of better management of those claims. Could you maybe help us parse out the breakdown of that? I know Mark was helpful in providing some comments about the flu and other 1Q utilization issues. But just anything else, if you could sort of clarify at this point, how you're viewing any weather or flu items in the first quarter?
非常感謝讓我提問。也很感謝你們提到,超預期表現中有三分之二來自有利的理賠(claims)以及對理賠更好的管理。你們能否協助我們拆解一下其中的組成?我知道 Mark 針對流感以及第一季其他使用量(utilization)問題提供了一些說明。但如果可以的話,還有沒有其他資訊能在此時點更清楚說明:你們如何看待第一季的天氣或流感因素?
And then secondarily, in terms of some of those better management of claims, I appreciate you said that you're going to sort of flow those through for the rest of the year. Anything we should sort of think about in terms of that ramping up or should we think about that as relatively ratable across the rest of 2026?
其次,關於其中一些更好的理賠管理,我理解你們說會在今年剩餘期間把這些效益延續下去。那我們在模型上應該如何思考:這會在後續逐步拉升(ramping up),還是應該把它視為在 2026 年剩餘期間相對平均(ratable)?
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Elizabeth, thanks for the question. Let me start by framing the quarter because I think that's the cleanest way to answer your question as well as address sort of the guidance change that we put through. So in the first quarter, EPS did come in ahead of our initial outlook, and that included about $0.45 of core outperformance. About two-thirds of that or roughly $0.30 reflected underlying business favorability and the remaining $0.15 was really driven by seasonality-related timing dynamics.
Elizabeth,謝謝你的提問。我先用第一季的框架來回答,因為我認為這是最清楚的方式,也能一併說明我們所做的財測(guidance)調整。第一季 EPS 的確高於我們最初的展望,其中包含約 0.45 美元的核心超預期(core outperformance)。其中約三分之二、也就是大約 0.30 美元,反映的是基本業務面的有利因素;其餘 0.15 美元主要是由季節性相關的時點因素(timing dynamics)所驅動。
The underlying favorability was concentrated primarily in our Health Benefits business, and that did reflect better claims experience than we had assumed, including to the point you made, a less severe flu-like season that was embedded in our first-quarter outlook, and that accounted for about $0.10-ish of that benefit.
基本面有利因素主要集中在我們的健康福利(Health Benefits)業務,反映的是理賠經驗(claims experience)優於我們原先假設;也包括你提到的重點:我們第一季展望中所納入的流感樣季節(flu-like season)嚴重程度較高,但實際上較不嚴重,這大約貢獻了 0.10 美元左右的效益。
And so the remaining outperformance was really timing related. And as we noted in our prepared remarks this morning, primarily came from our ACA business, and that's simply driven by that higher mix of bronze plans, which we expect will defer a portion of planned costs into the back half of the year. So if I turn -- if I brought that all together and I turn to the guidance range, we did increase that full-year EPS guide by $1.25 per -- relative to our prior outlook.
因此,其餘的超預期表現主要與時點有關。如同我們今天早上在事先準備的講稿中提到的,主要來自我們的 ACA 業務,原因很單純:青銅級(bronze)方案的組合占比更高,我們預期這會把一部分原本規劃的成本遞延到下半年。所以把這些整合起來、再回到財測區間,我們把全年 EPS 指引相較於先前展望上調了每股 1.25 美元。
And I would say of that increased $0.25 reflects that portion of the underlying nonseasonal business favorability we saw in the quarter. And of course, the remaining $1 was a nonrecurring item. And one last point, just from a modeling perspective, that dollar should clearly be excluded from the 2026 earnings baseline. So when you think about us returning to at least 12% EPS growth in 2027, that growth is off of an ending 2026 baseline at this point in time of at least $25.75.
我會說,在這次上調中,有 0.25 美元反映的是我們在本季看到的那部分非季節性(nonseasonal)的基本面有利因素。當然,其餘 1 美元是一次性(nonrecurring)項目。最後補充一點,從建模角度來看,這 1 美元應該明確地從 2026 年的獲利基期(earnings baseline)中排除。因此,當你們思考我們在 2027 年回到至少 12% 的 EPS 成長時,該成長是以目前時點 2026 年期末基期至少 25.75 美元為基礎。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Next question, please.
請下一題。
Operator
Operator
Kevin Fischbeck, Bank of America.
Kevin Fischbeck,Bank of America。
Kevin Fischbeck - Analyst
Kevin Fischbeck - Analyst
Can we maybe go back to the exchange commentary. I guess we've been trained to look at better-than-expected enrollment sometimes as a red flag. So I just wanted to see if you could give any color about whether the high enrollment has come with any change in the underlying risk pool that you're seeing? And I guess last year, there was a change in the risk pool in part because there was a group of people coming -- losing Medicaid coverage coming on to the exchanges. Are you seeing any signs that that's a potential pressure happening this year?
我們能否回到交易所(exchange)的評論。我想我們通常被訓練成:有時候投保人數(enrollment)優於預期反而是一個警訊。所以我想請你們提供一些說明:你們觀察到高投保人數是否伴隨著你們所看到的基礎風險池(risk pool)出現任何變化?另外,去年風險池有變化,部分原因是有一群人失去 Medicaid 保障後轉到交易所。你們今年是否看到任何跡象顯示,這可能成為今年的壓力來源?
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Thanks for the question. Let me start off by saying we took a fairly prudent view when pricing 2026. And we did that really with the assumption that while much of the impact from the expiration of the enhanced premium subsidies would occur in the first year, it's going to take a little while for the risk pool stabilization to ultimately play out.
謝謝你的提問。我先說,我們在訂定 2026 年費率時採取了相當審慎的看法。我們這麼做,主要是假設:雖然加強版保費補貼(enhanced premium subsidies)到期的影響多數會在第一年發生,但風險池的穩定化(stabilization)最終完全反映出來仍需要一些時間。
I'd also note it's still early in the year and more time is going to be needed for those retention patterns or member retention patterns really to settle out and for claims to mature before we have a fully developed view of the morbidity profile of the risk pool this year. That said, one really early indicator that we have seen prior claims experience for renewing members in paid status running moderately higher than for the cancel or nonpayment cohorts.
我也想指出,現在仍是年初,還需要更多時間,讓這些留存模式或會員留存模式真正趨於穩定,並讓理賠逐步成熟,之後我們才能對今年風險池的疾病率(morbidity)輪廓形成完整的看法。話雖如此,我們看到的一個非常早期指標是:續保且仍在繳費狀態的會員,其既往理賠經驗的已付理賠水準,適度高於取消或未繳費族群。
And that did support our view that (inaudible) here has increased the morbidity of the remaining pool. But importantly, that dynamic, that is tracking consistent with or even better than how we price the business in 2026. And so sort of to conclude here, I feel very good about our membership mix, and I feel very encouraged by that shift towards bronze, both in our book of business, but also broadly across the market itself.
這也支持了我們的看法,即(聽不清)在此提高了剩餘風險池的疾病率。但重要的是,這種動態的追蹤結果與我們在 2026 年對該業務的定價假設一致,甚至更好。因此在此做個總結,我對我們的會員結構感到非常有信心,也對向青銅級(bronze)轉移的趨勢感到非常鼓舞,這不僅發生在我們的業務組合中,也更廣泛地出現在整體市場。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Next question, please.
下一個問題,請。
Operator
Operator
Dave Windley, Jefferies.
Jefferies 的 Dave Windley。
David Windley - Equity Analyst
David Windley - Equity Analyst
Thanks for taking my question. I wanted to come back to Medicaid. Gail, you reiterated the comment that you think '26 is trough. I wanted to understand the assumptions embedded in that for '27 in terms of your expectations for member attrition from work requirement implementation and things of that sort? And then also ask where your thinking is around stay or leave state by state in situations where rate discussions are perhaps not moving in the direction that you'd like them to?
謝謝讓我提問。我想回到 Medicaid(醫療補助)這個話題。Gail,你重申你認為 2026 年是谷底。我想了解你對 2027 年的假設,特別是你對因工作要求(work requirement)落地實施等因素所導致的會員流失(attrition)的預期是什麼?另外也想請教,在某些州的費率討論可能沒有朝你們希望的方向發展時,你們對於逐州「留下或退出」的思考是什麼?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
So let me take the second part of the question first, and then I'll ask Mark to comment on the membership assumptions. We -- so as Felicia shared with you on Medicaid, we're having very constructive discussions with the states. While the rates are still lagging, we've seen, I think, positive movement in states trying to be constructive. And it's not only about the rates, it's also about the actions that we can take on benefits as well as the changes that we're making to our networks and other things.
我先回答問題的第二部分,然後我會請 Mark 針對會員假設做說明。我們——如 Felicia 跟各位分享的,在 Medicaid 方面,我們正與各州進行非常具建設性的討論。雖然費率仍然落後,但我認為我們看到各州在嘗試以建設性的方式推進,出現了正向的進展。而且這不僅僅是費率問題,也包括我們在給付項目(benefits)上可以採取的行動,以及我們對醫療網絡(networks)所做的調整和其他事項。
That being said, as I shared, I think, on the last call, where we don't see a sustainable path to profitability in a state, we will exit. I don't think we're at that stage with states. I just want to be clear. But again, we also are taking the view of, look, we need a sustainable path to this business. We do think it's an important business, both between our Medicare and Medicaid business in terms of how we serve our duals. But again, we will take a look to make sure that these rates are sustainable and that the capital we put into it can be returned.
話雖如此,正如我分享的,我想是在上一次電話會議上提到的:在某個州如果我們看不到可持續的獲利路徑,我們就會退出。我認為我們目前還沒有到那個階段。我只是想把話說清楚。但同樣地,我們也抱持這樣的觀點:我們需要這項業務有一條可持續的發展路徑。我們確實認為這是一項重要的業務,尤其在我們的 Medicare 與 Medicaid 業務之間,對於我們如何服務雙重資格者(duals)而言很重要。但同樣地,我們會檢視以確保這些費率是可持續的,並且我們投入的資本能夠獲得回報。
So with that, I'll ask Mark to comment just on how we're thinking about membership evolving over this year and next year.
因此,我會請 Mark 就我們如何看待今年與明年會員數的演變做個說明。
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Thanks for the question here. I think modestly better Medicaid membership at year-end 2026 would not change our view that 2026 is the trough year for Medicaid margins. And if membership comes in somewhat better than we expected, the most likely explanation here is really timing, really that some eligibility-driven attrition would occur later than we had assumed. And that could, in theory, to your question, shift a portion of that membership and acuity pressure into 2027.
謝謝這個問題。我認為,即使 2026 年底 Medicaid 會員數略優於預期,也不會改變我們認為 2026 年是 Medicaid 利潤率谷底年的看法。如果會員數確實比我們預期稍好,最可能的解釋其實是時點因素,也就是某些由資格(eligibility)驅動的流失會比我們原先假設的更晚發生。而這在理論上,回到你的問題,可能會把一部分會員數與病情嚴重度(acuity)壓力移轉到 2027 年。
But we would not expect any incremental pressure to be or we would expect any incremental pressure to be much more measured than what we would have experienced during the post-PHE period. And the key point here is because it's much more targeted, it's much more concentrated in that expansion population rather than being broad-based across the Medicaid book.
但我們不會預期會有額外壓力——或者說,我們預期任何額外壓力都會比我們在 PHE(公共衛生緊急狀態)後期間所經歷的要溫和得多。關鍵點在於,因為它更具針對性,且更集中在擴張族群(expansion population),而不是廣泛地分布在整個 Medicaid 業務組合中。
And then just as importantly, and you heard this from Gail, that does not change our belief in the setup that we see for 2027. And we do believe 2027 is going to continue to benefit from better rate alignment as states incorporate more of that recent experience into their rate setting cycles. And certainly, while work requirements and community engagement requirements may create some additional pressure over time. I just want to emphasize the point, we do expect that impact to be much more phased and much more manageable than the redetermination cycle historically.
同樣重要的是,而且你也從 Gail 那裡聽到了,這不會改變我們對 2027 年所看到的有利態勢的看法。我們確實相信,隨著各州在費率制定週期中納入更多近期經驗,2027 年將持續受惠於更好的費率對齊(rate alignment)。當然,雖然工作要求與社區參與要求(community engagement requirements)可能會隨時間帶來一些額外壓力。但我想強調的是,我們預期其影響會更分階段(phased)且更可控,遠比歷史上的重新認定(redetermination)週期更容易管理。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thank you, Mark. Next question, please.
謝謝你,Mark。下一個問題,請。
Operator
Operator
Erin Wright, Morgan Stanley.
Morgan Stanley 的 Erin Wright。
Erin Wright - Analyst
Erin Wright - Analyst
So AI and automation across just managed care in general has been a big question area for investors. I guess, can you talk about some of the proof points today or progress on that front, quantify any of those efficiency gains or maybe your long-term goals as it relates to that? And how are you tracking in terms of the associated incremental investments? How do you see that playing out as well as we head into '27, '28? Any context there would be great.
AI 與自動化在整體管理式醫療(managed care)領域一直是投資人很關注的議題。我想請你談談目前有哪些佐證(proof points)或進展;能否量化其中一些效率提升,或你們在這方面的長期目標?以及在相關的增量投資方面,你們的進度如何?當我們邁向 2027、2028 年時,你們認為這會如何發展?若能提供一些背景脈絡會很有幫助。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Great. Well, thanks for the question, Erin. I think it's a great question in terms of how we're thinking about AI. And I think it's important as we talk about AI to step back because fundamentally, we see it and our technology strategy as supporting our overall strategy, which, as I said, is really very simple, make healthcare more affordable and make it simpler and more personalized for the people we serve. In terms of investments, we're investing more than $1 billion in digital and AI-enabled capabilities to support that strategy.
好的。Erin,謝謝你的提問。我認為這是一個很好的問題,關於我們如何思考 AI。我也認為在談 AI 時,重要的是先退一步看,因為從根本上,我們把 AI 與我們的科技策略視為支撐整體策略的工具;如我所說,我們的策略其實很簡單:讓醫療更可負擔,並讓我們所服務的人獲得更簡單、更個人化的體驗。在投資方面,我們正投入超過 10 億美元於數位與 AI 賦能(AI-enabled)能力,以支持該策略。
And I think the key point that I really just want to start with is we're not approaching AI as a separate technology element or experimentation. We're looking at things that will scale and support those absolute core things of our business. So to give you some specifics, we're embedding it, I would say, in practical ways, first to help us reduce costs and again, to simplify experiences and then take administrative costs and complexity out for ourselves.
我想先強調的一個重點是:我們並不是把 AI 當作一個獨立的技術要素或實驗來推進。我們關注的是能夠規模化(scale)並支撐我們業務絕對核心事項的應用。因此,給你一些具體例子:我們以務實的方式把它嵌入(embedding)到流程中,首先是幫助我們降低成本,同時簡化體驗,並為我們自己移除行政成本與複雜度。
So I'll walk in a couple of examples. One, for our members, that's really about making it easier to navigate. Healthcare is really complicated. When we look at where we've already invested, our AI-enabled virtual assistant, I think, is a really good example. We already have 22 million commercial members on that using it regularly, and it's helping people get answers fast with less friction. And we're seeing that dramatically improve, for example, our consumer effort scores.
我舉幾個例子說明。第一,對會員而言,重點在於讓就醫與使用服務更容易導覽。醫療真的很複雜。就我們已經投入的部分來看,我們的 AI 賦能虛擬助理就是一個很好的例子。目前我們已有 2,200 萬名商業保險會員定期使用它,幫助人們以更少摩擦更快取得答案。而且我們看到這顯著改善了例如我們的消費者付出努力分數(consumer effort scores)。
We're also being more personal. And I think that's another really important part of how we can deploy this technology through Sydney, which is our personalized matching tool, where we help actually using over 500 data points, match people to the right care providers. More than 20% of our members have already connected and are finding the right providers.
我們也在做得更個人化。我認為這也是我們如何透過 Sydney(我們的個人化配對工具)部署這項技術的另一個非常重要部分;我們實際上使用超過 500 個資料點,協助把人們配對到合適的照護提供者。已有超過 20% 的會員完成連結並找到合適的提供者。
So not only is that simpler for them, but quite frankly, brings them to our providers that are high-performing providers. And again, that helps drive better medical costs. On the clinical and care operations side, we see AI helping improve things around speed, accuracy, decision-making, strengthening payment integrity. And what that's doing is giving us information much earlier to identify outliers.
因此,這不僅讓他們的流程更簡單,而且坦白說,也把他們導向我們那些高績效的醫療提供者。同樣地,這有助於推動更好的醫療成本表現。在臨床與照護營運端,我們看到 AI 有助於提升速度、準確性與決策品質,並強化支付完整性(payment integrity)。而這帶來的效果是讓我們更早取得資訊,以辨識異常值(outliers)。
Again, that feeds into our ability to see trends faster and then take actions with our team around network, around clinical interventions. So over time, we see that as a real opportunity to manage costs. Right now, it's about getting information in our hands a lot faster. And I'll sort of close on a couple of final examples for care providers, it's really about reducing burden.
再者,這也強化了我們更快看見趨勢、並與團隊在網路(network)與臨床介入(clinical interventions)等面向採取行動的能力。因此,隨著時間推移,我們將其視為管理成本的真正機會。就目前而言,重點在於更快把資訊掌握在我們手上。我也用幾個照護提供者(care providers)的最後例子作結:核心其實是降低負擔。
We need to really reduce the friction and simplify workflows. That's a commitment that we've made. Health OS is an area that we've been investing over. You've heard us talk about it the last several years. And that's really about data sharing, reducing paperwork, and accelerating approvals. We're using it right now in our prior authorization commitments.
我們確實需要降低摩擦並簡化工作流程。這是我們已做出的承諾。Health OS 是我們持續投入的領域。過去幾年你們也聽我們談過。其重點在於資料共享、減少文書作業,以及加速核准。我們目前正把它用在事前授權(prior authorization)的承諾上。
And one of the areas that I know frustrates everyone is this lack of information and denials generally get caused because we don't get the right information. We see this technology and AI reducing those denials by more than almost 70%, and it eliminates a lot of the need for follow up and back and forth. So that's good for the system, and I think good for care providers.
我知道讓大家都感到挫折的一個面向,是資訊不足,而拒付(denials)通常是因為我們沒有取得正確資訊所造成。我們看到這項技術與 AI 能將這些拒付降低將近 70% 以上,並消除大量追蹤與來回往返的需求。因此這對整個體系是好事,我也認為對照護提供者是好事。
Then I'll just close, how else we're thinking about AI. We're leveraging it across our associates. More than 60,000 already have access to it. They're using it in their productivity tools. They're learning it. We have individuals signing up to understand how to use it. We have guardrails around that.
最後我也簡單收尾,談談我們還如何看待 AI。我們正把它運用在同仁(associates)各層面。已有超過 60,000 人可以使用。他們把它用在生產力工具上。他們也在學習。也有人主動報名了解如何使用。我們也設有相應的護欄(guardrails)。
We're obviously very cautious about making sure we use it the right way, but we think -- we see it as a productivity tool. So let me just step back. I know that was a lot, but we see it. We're encouraged by technology. It's not just pilots. It's embedded in our capabilities, and you're really going to see it come through in the results we have in the measures, not just in the dollars, but also in our [admin].
我們顯然非常謹慎,確保以正確方式使用它,但我們認為——我們把它視為一項生產力工具。所以讓我稍微退一步。我知道剛才資訊很多,但我們確實看到了。我們對科技感到振奮。這不只是試點(pilots)。它已嵌入我們的能力之中,你們將會在我們的成果與衡量指標上真正看到它的體現,不僅是在金額上,也會在我們的[admin] 上。
So thank you very much for the question. Next question, please.
非常感謝你的提問。請下一題。
Operator
Operator
Ben Hendricks, RBC Capital Markets.
Ben Hendricks,RBC Capital Markets。
Ben Hendrix - Analyst
Ben Hendrix - Analyst
I wanted to get a little bit more color on the site of care optimization actions you mentioned helping to control your cost trend. Yesterday, we heard your peer mentioned some notable reductions in hospital admissions and skilled nursing transfers through some heightened clinical review. And I'm wondering if you could share some anecdotes either within the Carelon risk-based programs or in the broader benefits business where you're seeing gains from those site of care efforts specifically?
我想更深入了解一些你提到、可協助控制成本趨勢的照護場域(site of care)最佳化措施。昨天我們聽到同業提到,透過更嚴格的臨床審查,住院收治與轉至專業護理機構(skilled nursing)的情況有顯著下降。我想請問你是否能分享一些案例,不論是在 Carelon 的風險承擔型(risk-based)方案內,或是在更廣泛的福利業務中,你們在哪些方面特別因這些照護場域措施而看到成效?
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Thanks very much for the question this morning. So just as a reminder, CareBridge is our home-based care platform focused on Medicaid and dual-eligible members, especially those with complex needs. And strategically, this is important for us because it extends Carelon's whole health model into the home, where obviously, better coordination can improve outcomes, lower total cost of care and then support stronger health plan performance.
非常感謝你今天早上的提問。先提醒一下,CareBridge 是我們的居家照護平台,聚焦於 Medicaid 與雙重資格(dual-eligible)會員,特別是需求複雜者。在策略上,這對我們很重要,因為它把 Carelon 的全人健康(whole health)模式延伸到家中;在那裡,更好的協調顯然能改善結果、降低總照護成本,並進一步支持更強的健康計畫績效。
We're also very pleased with how CareBridge is ultimately integrating into the broader Carelon ecosystem. I'd say first-quarter results are very much in line with our expectations for CareBridge. But we are seeing continued signs of improvement as we scale that platform and drive operational efficiencies across the book.
我們也非常樂見 CareBridge 最終如何整合進更廣泛的 Carelon 生態系。我會說第一季的結果非常符合我們對 CareBridge 的預期。但隨著我們擴大該平台規模,並在整體業務組合(book)推動營運效率,我們也持續看到改善的跡象。
We are also expanding CareBridge in ways that deepen both its reach, R-E-A-C-H, and its value. And intentionally, we have launched additional Medicaid home and community-based support programs in several states, which has deepened our market penetration. And as a result of that, we are seeing early indications of that improved cost of care performance, especially as those capabilities are ultimately embedded into our market.
我們也正以深化其觸及(reach,R-E-A-C-H)與價值的方式擴展 CareBridge。我們也有意在數個州推出額外的 Medicaid 居家與社區式支持(home and community-based support)方案,進一步加深我們的市場滲透率。因此,我們已看到照護成本績效改善的早期跡象,特別是當這些能力最終嵌入我們的市場之後。
So to your question, when we talk about site of care optimization through CareBridge, it's really about keeping members aligned to the right level of care, reducing unnecessary facility-based utilization and using that home as a more effective and lower cost setting for managing those complex and chronic needs.
回到你的問題,當我們談到透過 CareBridge 進行照護場域最佳化時,重點其實是讓會員對應到正確的照護層級,減少不必要的機構型(facility-based)使用,並把「家」作為更有效、成本更低的場域來管理那些複雜與慢性需求。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thank you, Mark. I might ask Aimee Dailey, who leads our Government business, to also comment on how we're deploying that inside of the Health Benefits business. Aimee?
謝謝你,Mark。我也想請負責政府業務(Government business)的 Aimee Dailey 補充說明,我們如何在健康福利(Health Benefits)業務中部署這些作法。Aimee?
Aimee Dailey - President, Government Health Benefits
Aimee Dailey - President, Government Health Benefits
Yeah. No, thank you, Gail. Really, one of the greatest things about CareBridge is its ability to engage members in a place that they're comfortable being engaged. And that engagement rate allows better reach, better access for those members to their healthcare and actually has created a fair amount of ER avoidance and improvement in PCP visits, which allows us then to get quality gaps in care closed and really make sure that these members are getting better outcomes in the long term.
好的。不,謝謝你,Gail。其實,CareBridge 最棒的一點,是它能在會員覺得舒適的地方與他們互動。而這樣的互動率帶來更好的觸及與更好的醫療可近性,並且確實創造了相當程度的急診(ER)避免,以及基層照護醫師(PCP)就診的改善,讓我們得以補齊照護品質缺口(quality gaps in care),並真正確保這些會員長期能獲得更好的結果。
And we're really -- very pleased with what we're seeing and the early adoption of our CareBridge model across our duals business. And that dual business is where we see really a high level of need in that engagement. And so very pleased with how we've been able to embrace that CareBridge model.
我們對目前看到的情況以及 CareBridge 模式在我們雙重資格(duals)業務中的早期採用都非常——非常滿意。而雙重資格業務正是我們看到互動需求非常高的地方。因此,我們也很高興能夠採納並推動這個 CareBridge 模式。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Thank you. Next question, please.
謝謝。請下一題。
Operator
Operator
Sarah James, Cantor Fitzgerald.
Sarah James,Cantor Fitzgerald。
Sarah James - Analyst
Sarah James - Analyst
Was there any takeaways on where you sit versus the industry from the new March Wakely data? I think they may have provided some context around average premiums or metal tiers. And then on the bronze shift you mentioned, can you quantify how much your mix moved? And just give us an idea of the delta between peak and trough MLR between bronze and silver. Is that just like a couple of hundred basis point or is it larger than that?
針對 3 月最新的 Wakely 資料,你們是否有任何關於自身相較於產業位置的重點觀察?我想他們可能提供了一些關於平均保費或金屬層級(metal tiers)的背景。另外,關於你提到的青銅(bronze)轉移,你能量化你們的組合(mix)移動了多少嗎?也請給我們一個概念:青銅與白銀(silver)之間,MLR 在高峰與低谷的差距(delta)大概是多少?是大約幾百個基點,還是比那更大?
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
Thanks very much for the question here. The early Wakely report has been a helpful input because it provides additional visibility into market size, metal mix and enrollment patterns. And importantly, the report from our perspective supports our view that we are seeing a greater shift towards bronze and a greater share of new sales, both of which obviously have implications for our relative risk to the market. And therefore, to an earlier question that was asked around risk adjustment.
非常感謝你的提問。Wakely 的早期報告是一個有幫助的輸入,因為它讓我們對市場規模、金屬組合(metal mix)與投保(enrollment)型態有更多能見度。更重要的是,從我們的角度來看,該報告支持我們的看法:我們正看到更明顯地轉向青銅方案,以及新銷售占比提高;這兩者顯然都會影響我們相對於市場的風險狀況。因此也呼應先前關於風險調整(risk adjustment)的提問。
I'd really caution it's still an early data set from Wakely. It does not fully capture the impact of retro cancellations, nonpayment behavior or even maturing cohorts. And so I'd say while the report is useful, visibility is going to continue to improve as we get more effectuation data and cohort-based information over the coming months.
我也要提醒,Wakely 這仍是一份早期資料集。它尚未完整反映追溯取消(retro cancellations)、未繳費行為(nonpayment behavior),甚至是成熟中的投保批次(maturing cohorts)的影響。因此我會說,雖然這份報告有用,但隨著未來幾個月我們取得更多實際生效(effectuation)資料與以 cohort 為基礎的資訊,能見度仍會持續提升。
All in, I think the most important point here is we feel very comfortable with our pricing and how we positioned our products for sustainability in the ACA market this year. And then to your question on specific splits, we are seeing a much more balanced bronze-silver mix this year come through based on the new sales.
整體而言,我認為最重要的一點是:我們對今年在 ACA 市場的定價,以及我們為永續性所做的產品定位感到非常有信心。至於你問到的具體拆分,今年依新銷售來看,我們看到青銅—白銀的組合更為均衡。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Next question, please.
下一個問題,請。
Operator
Operator
Jason Cassorla, Guggenheim.
Jason Cassorla,Guggenheim。
Jason Cassorla - Equity Analyst
Jason Cassorla - Equity Analyst
I wanted to ask a little bit more on the return to at least 12% EPS growth in '27. You've got margin expansion opportunity across most of your end markets. You've talked about the early benefits of AI and investment spend. But I guess could you help frame how we should be thinking about the components of that 2027 growth, including how much of that is predicated on pricing and trend that you can control or impact.
我想再多問一點關於在'27年回到至少12% EPS成長的部分。你們在大多數終端市場都有毛利率擴張的機會。你們也談到AI與投資支出帶來的早期效益。但我想請你們協助框架一下,我們應該如何看待2027年成長的組成要素,包括其中有多少是建立在你們能控制或影響的定價與趨勢之上。
Or maybe said another way, to the degree that Medicaid margins remain pressured next year, how do you feel about the levers and growth opportunities across your other businesses that could offset to drive that at least 12% growth expectation?
或者換個說法,如果明年Medicaid的利潤率仍然承壓,你們如何看待在其他業務中可用的槓桿與成長機會,能夠抵銷並推動至少12%成長預期?
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Well, thanks for the question. I think it's important to first start with '26. And I think the headline around '26 is this is all about execution. And as you saw, we upped our guide to at least $26.75, reflecting that early execution while remaining grounded again in prudent, achievable expectations. Specific to your question, as we think about '27, we're confident in at least 12% adjusted EPS growth off of that earnings baseline, which now stands at $25.75, as Mark shared.
好的,謝謝你的提問。我認為首先從'26年談起很重要。而'26年的重點就是執行力。如你所見,我們把指引上調至至少26.75美元,反映出早期的執行成果,同時仍然以審慎、可達成的預期為基礎。針對你的問題,當我們看'27年時,我們有信心在這個獲利基準之上達成至少12%的調整後EPS成長;如Mark所分享,這個基準目前為25.75美元。
Over the past couple of years, and I want to reframe that we've made targeted investments in portfolio, pricing and operating discipline. And those were all designed to protect our earnings base and position us for the durable growth that we're projecting. We're leveraging the capabilities of our diversified platform, and I think that's really important. And there's three things I just want to underscore to your '27 question.
過去幾年,我想重新表述一下,我們在投資組合、定價與營運紀律方面進行了有針對性的投資。這些都是為了保護我們的獲利基礎,並讓我們為所預期的持續性成長做好定位。我們正在運用多元化平台的能力,我認為這點非常重要。針對你對'27年的問題,我想強調三點。
First, the key earnings levers are already in motion, and I think that's important. Those are the actions that we put in place in '25 and into '26, and those are across many of the things you said, pricing, care management, and portfolio positioning. Second, we're making meaningful investments in 2026. So as those investments mature and we realize returns on those initiatives, we're going to see a clear step-up for 2027.
第一,關鍵的獲利槓桿已經在運作中,我認為這很重要。這些是我們在'25年以及進入'26年所部署的行動,涵蓋你提到的許多面向:定價、照護管理,以及投資組合定位。第二,我們在2026年正在進行具實質意義的投資。因此,當這些投資成熟並且我們實現這些計畫的回報時,2027年將會看到明顯的躍升。
And third, again, the path isn't predicated on any single assumption. And I think that's really important as you think about our portfolio. It's built on many and multiple independent levers, and it's disciplined execution across both Health Benefits and Carelon. So those are the factors as I think about it, that give us confidence in achieving the earnings growth consistent with the long-term growth algorithm that we talked about through '27.
第三,再次強調,這條路徑並不建立在任何單一假設之上。當你思考我們的投資組合時,這點非常重要。它是建立在許多、且彼此獨立的多重槓桿之上,並且在Health Benefits與Carelon兩大板塊都需要有紀律的執行。因此,這些因素讓我們有信心能達成與我們所談到、延伸至'27年的長期成長演算法一致的獲利成長。
So thank you for the question. And next question, please. This will be our last question.
所以謝謝你的提問。下一個問題,請。這將是我們最後一個問題。
Operator
Operator
George Hill, Deutsche Bank.
George Hill,德意志銀行。
George Hill - Analyst
George Hill - Analyst
Thanks for squeezing me in, This one is probably for Mark. Mark, we saw a pretty big step-up in base claims payable, both sequentially and year over year. I was wondering two things. Number one, might you be able to unpack kind of what drove that for us? Was it membership mix? Was it the exiting of Part D? Was it like legacy claims? And kind of how should we think about how that number trends through the balance of the year?
謝謝讓我插個問題,這題可能是問Mark的。Mark,我們看到基本應付理賠(base claims payable)無論是季比或年比都有相當大的跳升。我想問兩點。第一,你能否拆解一下是什麼驅動了這個變化?是會員結構(membership mix)嗎?是退出Part D嗎?是像是歷史理賠(legacy claims)嗎?以及我們應該如何看待這個數字在今年剩餘期間的走勢?
Mark Kaye - Chief Financial Officer, Executive Vice President
Mark Kaye - Chief Financial Officer, Executive Vice President
George, thanks very much for the question. So DCP ended the quarter at 46.6 days. That was up 5.3 days from year end, and that was driven mainly by normal first-quarter seasonality and higher medical claims inventory across the business.
George,非常感謝你的提問。所以DCP在本季末為46.6天。較年末增加5.3天,主要是由於第一季正常的季節性因素,以及全業務較高的醫療理賠待處理量所致。
A little bit deeper here. Commercial was affected in part by individual mix dynamics that we've discussed. Medicaid and Medicare really reflect that typical earlier slowdown in claims payment cycle. And really, the main takeaway here is the DCP result was largely a seasonal and mix-related movement. I wouldn't say it reflects any change in our underlying reserve approach.
再深入一點。商業保險部分,部分受到我們先前討論過的個人市場組合動態影響。Medicaid與Medicare則主要反映理賠支付週期在年初通常會較早放緩的情況。而最重要的結論是,DCP的結果大致是季節性與組合相關的變動。我不會說這反映了我們在基礎準備金方法上有任何改變。
On the prior year development, that was approximately $250 million in the first quarter. And it's really worth noting here around that number is that typically for prior year development, we reestablish that as margins and reserves through the normal process. And so it really doesn't have a material P&L impact.
至於前一年發展(prior year development),第一季約為2.5億美元。關於這個數字值得注意的是,通常針對前一年發展,我們會透過正常流程將其重新建立為利潤率與準備金的一部分。因此,它對損益表並沒有重大影響。
Thanks for the question.
謝謝你的提問。
Gail Boudreaux - President, Chief Executive Officer, Director
Gail Boudreaux - President, Chief Executive Officer, Director
Well, thank you. Thank you for the questions. And thank you, operator, and thanks to everyone on the line. As we move through 2026, our focus remains on operational execution, strengthening our diversified platform and building momentum across the enterprise. We're encouraged by our strong start to the year and the progress we're seeing.
好的,謝謝。謝謝各位的提問。也謝謝接線員,並感謝線上所有與會者。隨著我們邁入2026年,我們的重點仍然是營運執行、強化我們多元化的平台,並在整個企業內建立動能。我們對今年強勁的開局以及所看到的進展感到鼓舞。
Our strategy to improve affordability, simplify the experience for all of our consumers and care providers, and deliver better outcomes for the people we serve is what's driving durable financial performance over the long term for us. Thank you for your continued interest in Elevance Health, and have a great rest of the week.
我們改善可負擔性、為所有消費者與照護提供者簡化體驗,並為我們服務的人群帶來更佳結果的策略,正是驅動我們長期穩健財務表現的關鍵。感謝各位持續關注Elevance Health,祝各位本週接下來一切順利。
Operator
Operator
Ladies and gentlemen, a recording of this conference will be available for replay after 11:00 AM today through May 22, 2026. You may access the replay system at any time by dialing (800)-391-9853 and international participants can dial (203)-369-3269.
各位女士先生,本次會議的錄音將於今日上午11:00之後提供重播,並可回放至2026年5月22日。您可於任何時間撥打(800)-391-9853進入重播系統,國際與會者可撥打(203)-369-3269。
This concludes our conference for today. Thank you for your participation and for using Verizon conferencing. You may now disconnect.
今天的會議到此結束。感謝各位的參與,並感謝使用Verizon會議服務。您現在可以掛線。